Dr Brian Hendrich
Transcriptional control of stem cell fate
Laboratory: Cambridge Stem Cell Institute, Gleeson Building
Departmental Affiliation: Biochemistry
Brian Hendrich grew up near Seattle, Washington, and is conseqeuntly a consummate coffee snob. He got his PhD from Stanford University in 1995 working on X chromosome inactivation with Huntington Willard.
In 1995 he joined the lab of Adrian Bird at the University of Edinburgh and participated in the discovery and characterisation of a family of methyl-CpG binding proteins in mammals. In 2001 he started his own laboratory at the University of Edinburgh. In 2008 he moved to the Wellcome Trust Centre for Stem Cell Research in Cambridge.
He is currently a Wellcome Trust Senior Research Fellow in the Basic Biomedical Sciences, and Director of the PhD Programme in Stem Cell Biology and Medicine for the Wellcome Trust - MRC Cambridge Stem Cell Institute.
He can often be found cycling the quieter roads of East Anglia, in search of a hill.
Isaac Newton Trust, Wellcome, Microsoft Research
Single cell gene expression data from 8-cell (red), 16-cell (green) and 32-cell (blue) embryos visualised in a Diffusion plot. (O’Shaughnessy-Kirwan et al. 2015) (Image Credit Patrick Lombard)
Embryonic stem (ES) cells hold enormous promise for personalised medicine and drug discovery since they can be maintained indefinitely and are pluripotent. While pluripotency makes ES cells potentially very useful, it also presents a problem: how do you get them to make the cell type you want, and not one you don't? Differentiation of pluripotent cells is exquisitely organised during normal embryogenesis, but very hard to control in culture. Since all cells in an organism are genetically identical, the observable differences in their functions and behaviours come down to which genes they express and which genes they repress. Therefore in order to understand how to direct cellular identity, seek to understand how subtle differences in gene expression patterns in seemingly identical cells influence any subsequent differentiation decisions. By understanding how ES cells make different developmental decisions this work will bring the medical promise of stem cells closer to realisation.
Thomas Burgold, Robin Floyd, Sarah Gharbi, Bertille Montibus, Nicola Reynolds, Maria Xenophontos.
Follow us on Twitter: @BDH_Lab
Embryonic stem cells can either make more copies of themselves, or differentiate to form any cell type in the body. This means that they have the potential to form any tissue, that is, they are pluripotent. How pluripotent cells make the decision to differentiate, and which cell type to differentiate into, is defined by which genes the cell turns on, and which it turns off. Genes are encoded in the cell’s DNA, which gets packaged up in the cell with proteins into a structure called chromatin. My group studies the function of a group of proteins which can change the structure of chromatin, thereby turning genes up, down, or off, in pluripotent cells. Our key questions are: How do pluripotent cells control their gene expression in order to make developmental decisions? How does the function of chromatin modifying proteins precisely control gene expression patterns? We are addressing these questions by studying both embryonic stem cells, but also pluripotent cells that exist very early in mammalian development. We aim to better understand how cells make decisions during normal development, but also to understand how these processes occasionally go wrong and result in human diseases such as cancer.
Miller, A., Ralser, M., Kloet, S. L., Loos, R., Nishinakamura, R., Bertone, P., Vermeulen, M., and Hendrich, B. (2016). Sall4 controls differentiation of pluripotent cells independently of the Nucleosome Remodelling and Deacetylation (NuRD) complex. Development, 143(17): 3074-84. doi: 10.1242/dev.139113 PMCID:PMC5047675
- O'Shaughnessy-Kirwan A, Signolet J, Costello I, Gharbi S, Hendrich B. (2015). Constraint of gene expression by the chromatin remodelling protein CHD4 facilitates lineage specification. Development, 142(15), 2586–2597. PMCID:PMC4529036
- Knock E, Pereira J, Lombard PD, Dimond A, Leaford D, Livesey FJ, Hendrich B. (2015) The methyl binding domain 3/nucleosome remodelling and deacetylase complex regulates neural cell fate determination and terminal differentiation in the cerebral cortex. Neural Development. May 2;10:13. PMCID: PMC4432814
Reynolds N, Latos P, Hynes-Allen A, Loos R, Leaford D, O’Shaughnessy A, Mosaku O, Signolet J, Brennecke P, Kalkan T, Costello I, Humphreys P, Mansfield W, Nakagawa K, Strouboulis J, Behrens A, Bertone P, Hendrich B. (2012). NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. Cell Stem Cell 10(5): 583-594. PMCID:PMC3402183
Reynolds N, Salmon-Divon M, Dvinge H, Hynes-Allen A, Balasooriya G, Leaford D, Behrens A, Bertone P, Hendrich B. (2012) NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression The EMBO Journal, 31(3), 593–605. PMCID:PMC3273378